2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Cardiotoxicity of anthracyclines
D Cardinale, F Iacopo, CM Cipolla - Frontiers in cardiovascular …, 2020 - frontiersin.org
Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …
targeted cancer therapies. Both general measures and specific pharmacologic …
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects
P Di Nardo, C Lisanti, M Garutti, S Buriolla… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Neo/adjuvant therapy for early-stage breast cancer has become increasingly
common in the last few decades; as a consequence, the number of breast cancer survivors …
common in the last few decades; as a consequence, the number of breast cancer survivors …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or …
C Lewinter, TH Nielsen, LR Edfors, C Linde… - European heart …, 2022 - academic.oup.com
Aims Trastuzumab and anthracyclines, often used in the treatment of breast cancer, may
impair myocardial function, and reduce left ventricular ejection fraction (LVEF), potentially …
impair myocardial function, and reduce left ventricular ejection fraction (LVEF), potentially …
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
P Thavendiranathan, C Houbois… - European Heart …, 2023 - academic.oup.com
Background and aims Anthracyclines can cause cancer therapy-related cardiac dysfunction
(CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection …
(CTRCD). We aimed to assess whether statins prevent decline in left ventricular ejection …
Statin Exposure and Risk of Heart Failure After Anthracycline‐or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort …
H Abdel‐Qadir, D Bobrowski, L Zhou… - Journal of the …, 2021 - Am Heart Assoc
Background Statins are hypothesized to reduce the risk of cardiotoxicity associated with
anthracyclines and trastuzumab. Our aim was to study the association of statin exposure …
anthracyclines and trastuzumab. Our aim was to study the association of statin exposure …